H.C. Wainwright raised the firm’s price target on Nektar (NKTR) to $165 from $135 and keeps a Buy rating on the shares. The firm increased its probability of launch and peak penetration rates for rezpegaldesleukin in atopic dermatitis to 60% and 15%, from 50% and 10%, respectively. Nektar reported “robust” 52-week results from its ongoing Phase 2b REZOLVE-AD study, readily beating all bull case expectations, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTR:
- Nektar Advances Rezpegaldesleukin After Positive Phase 2b Data
- Nektar management to meet virtually with Piper Sandler
- Nektar Therapeutics: Share Price Dislocation Masks Rezpeg’s Underappreciated Atopic Dermatitis and Alopecia Areata Upside
- Nektar management to meet with H. C. Wainwright
- Septerna appoints Mark Wilson as chief legal officer